PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment
Silexion Therapeutics (NASDAQ: SLXN) has reported breakthrough preclinical data for its SIL204 therapeutic candidate, showing promising results in treating KRAS-driven cancers, particularly pancreatic cancer. The orthotopic model studies demonstrated:
- ~70% reduction in tumor cell bioluminescence in AsPC-1 model (KRAS G12D mutation)
- Dose-dependent tumor cell reductions in Panc-1 model
- Up to 80% overall tumor cell reduction in BxPC-3 model
Notably, this marks the first systematic validation of a therapy's ability to suppress metastatic spread through systemic administration. The precision medicine market is projected to grow from $102 billion in 2024 to $470 billion by 2034. Maxim Group maintains a 'Buy' rating with a $9 price target, representing a ~600% premium over current price. The company is preparing to unveil an expanded development plan for SIL204, potentially exploring broader clinical applications.
Silexion Therapeutics (NASDAQ: SLXN) ha riportato dati preclinici innovativi per il suo candidato terapeutico SIL204, mostrando risultati promettenti nel trattamento dei tumori guidati da KRAS, in particolare il cancro pancreatico. Gli studi su modelli ortotopici hanno dimostrato:
- riduzione di ~70% nella bioluminescenza delle cellule tumorali nel modello AsPC-1 (mutazione KRAS G12D)
- riduzioni delle cellule tumorali in base alla dose nel modello Panc-1
- fino all'80% di riduzione complessiva delle cellule tumorali nel modello BxPC-3
È importante notare che questo segna la prima validazione sistematica della capacità di una terapia di sopprimere la diffusione metastatica attraverso la somministrazione sistemica. Si prevede che il mercato della medicina di precisione crescerà da 102 miliardi di dollari nel 2024 a 470 miliardi di dollari entro il 2034. Maxim Group mantiene un rating 'Buy' con un obiettivo di prezzo di 9 dollari, che rappresenta un premio di ~600% rispetto al prezzo attuale. L'azienda si sta preparando a svelare un piano di sviluppo ampliato per SIL204, esplorando potenzialmente applicazioni cliniche più ampie.
Silexion Therapeutics (NASDAQ: SLXN) ha informado datos preclínicos innovadores sobre su candidato terapéutico SIL204, mostrando resultados prometedores en el tratamiento de cánceres impulsados por KRAS, especialmente el cáncer de páncreas. Los estudios en modelos ortotópicos demostraron:
- una reducción de ~70% en la bioluminiscencia celular tumoral en el modelo AsPC-1 (mutación KRAS G12D)
- reducciones dependientes de la dosis en el modelo Panc-1
- hasta un 80% de reducción general de células tumorales en el modelo BxPC-3
Notablemente, esto marca la primera validación sistemática de la capacidad de una terapia para suprimir la diseminación metastásica a través de la administración sistémica. Se proyecta que el mercado de la medicina de precisión crecerá de 102 mil millones de dólares en 2024 a 470 mil millones de dólares para 2034. Maxim Group mantiene una calificación de 'Buy' con un objetivo de precio de 9 dólares, lo que representa una prima de ~600% sobre el precio actual. La compañía se está preparando para revelar un plan de desarrollo ampliado para SIL204, explorando potencialmente aplicaciones clínicas más amplias.
Silexion Therapeutics (NASDAQ: SLXN)는 SIL204 치료 후보에 대한 혁신적인 전임상 데이터를 보고했으며, KRAS에 의해 유도된 암, 특히 췌장암 치료에서 유망한 결과를 보여주고 있습니다. 정위 모델 연구에서 다음과 같은 결과가 나타났습니다:
- AsPC-1 모델(KRAS G12D 변이)에서 종양 세포 생물 발광이 ~70% 감소
- Panc-1 모델에서 용량 의존적인 종양 세포 감소
- BxPC-3 모델에서 최대 80%의 종양 세포 감소
특히, 이는 치료법이 전신 투여를 통해 전이 확산을 억제할 수 있는 능력을 체계적으로 검증한 첫 번째 사례입니다. 정밀 의학 시장은 2024년 1,020억 달러에서 2034년까지 4,700억 달러로 성장할 것으로 예상됩니다. Maxim Group은 현재 가격에 비해 ~600% 프리미엄을 나타내는 9달러 목표가로 'Buy' 등급을 유지하고 있습니다. 회사는 SIL204에 대한 확장된 개발 계획을 발표할 준비를 하고 있으며, 잠재적으로 더 넓은 임상 응용을 탐색하고 있습니다.
Silexion Therapeutics (NASDAQ: SLXN) a rapporté des données précliniques révolutionnaires pour son candidat thérapeutique SIL204, montrant des résultats prometteurs dans le traitement des cancers induits par KRAS, en particulier le cancer du pancréas. Les études sur des modèles orthotopiques ont démontré :
- une réduction d'environ 70 % de la bioluminescence des cellules tumorales dans le modèle AsPC-1 (mutation KRAS G12D)
- des réductions des cellules tumorales dépendant de la dose dans le modèle Panc-1
- jusqu'à 80 % de réduction globale des cellules tumorales dans le modèle BxPC-3
Il est à noter que cela constitue la première validation systématique de la capacité d'une thérapie à supprimer la propagation métastatique par administration systémique. Le marché de la médecine de précision devrait passer de 102 milliards de dollars en 2024 à 470 milliards de dollars d'ici 2034. Maxim Group maintient une note 'Buy' avec un objectif de prix de 9 dollars, représentant un premium d'environ 600 % par rapport au prix actuel. L'entreprise se prépare à dévoiler un plan de développement élargi pour SIL204, explorant potentiellement des applications cliniques plus larges.
Silexion Therapeutics (NASDAQ: SLXN) hat bahnbrechende präklinische Daten für seinen therapeutischen Kandidaten SIL204 veröffentlicht, die vielversprechende Ergebnisse bei der Behandlung von KRAS-gesteuerten Krebsarten, insbesondere Bauchspeicheldrüsenkrebs, zeigen. Die Studien an orthotopischen Modellen haben Folgendes gezeigt:
- ~70% Reduktion der Tumorzell-Biolumineszenz im AsPC-1 Modell (KRAS G12D Mutation)
- Dosisabhängige Tumorzellreduktionen im Panc-1 Modell
- Bis zu 80% Gesamtreduktion der Tumorzellen im BxPC-3 Modell
Bemerkenswert ist, dass dies die erste systematische Validierung der Fähigkeit einer Therapie darstellt, die metastatische Ausbreitung durch systemische Verabreichung zu unterdrücken. Der Markt für Präzisionsmedizin wird voraussichtlich von 102 Milliarden Dollar im Jahr 2024 auf 470 Milliarden Dollar bis 2034 wachsen. Maxim Group hält eine 'Buy'-Bewertung mit einem Kursziel von 9 Dollar aufrecht, was einem ~600% Aufschlag gegenüber dem aktuellen Preis entspricht. Das Unternehmen bereitet sich darauf vor, einen erweiterten Entwicklungsplan für SIL204 zu enthüllen, wobei möglicherweise breitere klinische Anwendungen erkundet werden.
- None.
- None.
Silexion's Groundbreaking Orthotopic Model Data and the Potential Expansion of its Development Plan Position SIL204 as Potential Transformative Therapy; Wall Street Maintains Buy Rating and
The Scientific Breakthrough: Redefining Cancer Treatment Paradigms
Silexion's orthotopic model studies have unveiled remarkable capabilities of SIL204 that could revolutionize cancer treatment approaches. The research demonstrated unprecedented efficacy across multiple pancreatic cancer models, with results that challenge existing therapeutic limitations:
In the AsPC-1 model (KRAS G12D mutation), the therapy showed approximately
Market Context: Precision Oncology's Evolving Landscape
The precision medicine market is experiencing explosive growth, projected to expand from
Industry dynamics in the past few years underscore the value of groundbreaking oncology assets. Notable acquisitions like Pfizer's
Wall Street’s Bullish Take on Silexion: ‘Buy’ Rating
Maxim Group has maintained its analysis of Silexion, rating the company a ‘buy’ and giving the stock a
Upcoming Catalysts: An Expanded Development Plan
The company is preparing to unveil details of its expanded development plan, which could provide critical insights into: Potential expansion of SIL204's therapeutic reach, Strategy for advancing toward clinical trials, Exploration of additional cancer indications.
With data analysis complete and initial results promising, Silexion appears positioned at a potentially transformative moment in its development of KRAS-targeting therapies.
The precision oncology sector continues to evolve rapidly, and Silexion Therapeutics has demonstrated a capability to push the boundaries of current treatment paradigms. As the company moves forward, its innovative approach to addressing KRAS-driven cancers remains a critical development to watch.
News Highlights from Silexion
- Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
- Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
- Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
>> Click here to Subscribe for more updates like this or go to https://www.pesgresearch.com/subscribe
* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published PESG Research, a promotional content brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains paid promotional content related to Silexion Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This alert has not been reviewed or approved by Silexion Therapeutics prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. We are not responsible for the price targets mentioned in this article nor do we it endorse them, they are quoted based on publicly available news reports. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317119505/en/
PESG Editorial Desk
ronald@futuremarketsresearch.com
Source: PESG Research